Coherus Oncology
CHRS
174 hedge funds and large institutions have $743M invested in Coherus Oncology in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 69 increasing their positions, 59 reducing their positions, and 23 closing their positions.
30% more capital invested
Capital invested by funds: $572M → $743M (+$171M)
17% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 59
9% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 23
1% less funds holding
Funds holding: 176 → 174 (-2)
2.38% less ownership
Funds ownership: 101.92% → 99.54% (-2.4%)
99% less call options, than puts
Call options by funds: $4K | Put options by funds: $679K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
+$8.97M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.37M |
| 3 |
Two Sigma Investments
New York
|
+$3.55M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.49M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$20M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12.9M |
| 3 |
JP Morgan Chase
New York
|
-$3.65M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.21M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.81M |
CHRS Hedge Fund Activity: Q3 2022 in Review
174 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2022, worth a combined $743M — up 30% from $572M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of CHRS and 21 opened new positions — a net loss of 2 holders — while 59 trimmed existing stakes and 69 added.
The largest buyer was Disciplined Growth Investors, adding an estimated $8.97M. The largest seller was Perceptive Advisors, cutting an estimated $20M.
- 174 institutional investors held Coherus Oncology (CHRS) as of Q3 2022, down from 176 in Q2 2022.
- Funds reported $743M of Coherus Oncology stock for Q3 2022, up 30% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q3 2022 and 23 closed out, a net change of -2 holders.
- The largest Coherus Oncology buyer in Q3 2022 was Disciplined Growth Investors, an estimated $8.97M added.
- The largest Coherus Oncology seller in Q3 2022 was Perceptive Advisors, an estimated $20M sold.
Based on aggregated 13F filings for Q3 2022.